(2000), Horm Res 53(Suppl 3), PubMed 10971106 Statistics from preclinical literature AOD-9604 = modified fragment of hGH 177191 + N-terminal Tyr (sequence Tyr-Leu-Arg-Ile-Val-Gln-Cys-Arg-Ser-Val-Glu-Gly-Ser-Cys-Gly-Phe), molecular weight 1815.1 Da Developed at Metabolic Pharmaceuticals (Australia) based on the work of professor Frank Ng (Monash University) in the 1990s Standard experimental dose in obesity clinical trials: 1 mg/day subcutaneously (Phase 2b, Heffernan et al.) Mechanism: stimulation of 3-adrenergic receptors in adipose tissue, increased lipolysis and fatty acid oxidation without activation of the hGH receptor (no IGF-1 increase) Phase 2b clinical trial (2007, 300 patients): weight reduction ~2.8 kg vs placebo over 12 weeks FDA status: NDI rejection (2014) as a dietary supplement

As the nations leader in aesthetic dermatology, we bring together state-of-the-art technology, a team of licensed medical professionals, and nearly two decades of clinical experience to deliver real results safely and consistently
We tailor the treatment to your specific needs, ensuring you receive the right dose of B12 to address your deficiency
It's one of the most frequently submitted drug codes alongside 96372, and it's also one of the most frequently denied under Medicare when the diagnosis doesn't meet LCD criteria
Not a medicine Not a dietary supplement Not a food or cosmetic product Not intended for human use Not intended for veterinary use Not supplied for any healthcare or consumer application Purchasers are responsible for ensuring that products are handled, stored and used in accordance with applicable laws, regulations and institutional research protocols
Provides antioxidant support for muscle and metabolic health